Antibodies that bind Zika virus envelope protein and uses thereof

Patent metadata

Field	Value
Publication number	US-10829545-B2
Application number	US-201715783655-A
Country	US
Kind code	B2
Filing date	Oct 13, 2017
Priority date	Oct 13, 2016
Publication date	Nov 10, 2020
Grant date	Nov 10, 2020

Abstract

Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

First claim

The invention claimed is:

1. An isolated monoclonal antibody which specifically binds Zika virus envelope protein, or antigen binding portion thereof of, comprising heavy and light chain CDRs, wherein
(i) heavy chain CDR1 comprises GFSFSTY (SEQ ID NO: 21);
(ii) heavy chain CDR2 comprises SGEGDS (SEQ ID NO: 27);
(iii) heavy chain CDR3 comprises GYSNFYYYYTMDA (SEQ ID NO: 32);
(iv) light chain CDR1 comprises RATQSISTFLA (SEQ ID NO: 38);
(v) light chain CDR2 comprises DASTRAS (SEQ ID NO: 44); and
(vi) light chain CDR3 comprises QQRYNWPPYS (SEQ ID NO: 50).

2. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , having neutralizing activity against Zika virus.

3. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgD, and an IgE antibody.

4. The isolated monoclonal antibody, or antigen binding portion thereof, according to claim 3 , wherein the antibody is an IgG1 antibody.

5. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 1 , and a pharmaceutically acceptable carrier.

6. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , comprising a heavy chain variable region, wherein the heavy chain variable region comprises a lysine at position 82B, numbering according to Chothia.

7. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 6 , having neutralizing activity against Zika virus.

8. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 6 , wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgD, and an IgE antibody.

9. The isolated monoclonal antibody, or antigen binding portion thereof, according to claim 8 , wherein the antibody is an IgG1 antibody.

10. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 6 , and a pharmaceutically acceptable carrier.

11. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , comprising heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NOs: 6 and 15, respectively.

12. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 11 , having neutralizing activity against Zika virus.

13. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 11 , wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgD, and an IgE antibody.

14. The isolated monoclonal antibody, or antigen binding portion thereof, according to claim 13 , wherein the antibody is an IgG1 antibody.

15. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 11 , and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 4 , and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 9 , and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 14 , and a pharmaceutically acceptable carrier.

Assignees

• Massachusetts Inst Technology
• Nat Univ Singapore

Inventors

• Sasisekharan Ram
• Tharakaraman Kannan
• Chan Kuan Rong
• Watanabe Satoru
• Vasudevan Subhash G
• Ooi Eng Eong

Classifications

• C07K16/116 Primary

  Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C07K16/10

  RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title